<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343272">
  <stage>Registered</stage>
  <submitdate>28/07/2011</submitdate>
  <approvaldate>12/08/2011</approvaldate>
  <actrnumber>ACTRN12611000857909</actrnumber>
  <trial_identification>
    <studytitle>Human Papillomavirus (HPV) infection in young men who have sex with men</studytitle>
    <scientifictitle>HPV infection in young men who have sex with men</scientifictitle>
    <utrn>NA</utrn>
    <trialacronym>HYPER</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Human papillomavirus infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cohort study of HPV infection over a 12 month period.  Each participant will have a three samples taken for HPV DNA (genital, throat, and anal) and serology taken for HPV DNA antibodies.  These samples (HPV DNA and serology) will be taken at base line, 3 months, 6 months, and 12 months (4 time periods).</interventions>
    <comparator>NIL</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HPV DNA detected at throat or genital or anus during any of the observation periods</outcome>
      <timepoint>at t=0, t=3 months, t=6 months, t=12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>HPV positive serology or HPV RNA detction</outcome>
      <timepoint>at t=0, t=3 months, t=6 months, t=12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men aged 16 to 20 
Report previous sexual contact (any type of sexual contact) with at least one other man ever
Able to complete all study requirements including questionnaire in English and completion of 4 visits</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>20</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>NIL</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Convenience sample</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>The Alfred 

P.O Box 315
Prahran. Vic. 3181.</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck</fundingname>
      <fundingaddress>MSD 
Level 4, 66 Waterloo Rd, 
North Ryde, NSW 2113 
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck</othercollaboratorname>
      <othercollaboratoraddress>MSD 
Level 4, 66 Waterloo Rd, 
North Ryde, NSW 2113 
Australia</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Studies indicate that men who have sex with men (MSM) have a high prevalence of anogenital Human papillomavirus (HPV) infection and increased risk for HPV related anogenital lesions including anogenital warts, anal intraepithelial neoplasia ( the abnormal proliferation of cells) and anal cancer. Currently in Australia, HPV vaccine for men is not covered by programs. This study will explore the prevalence of persistent HPV infection, distinguishing this from transient HPV infection and sexual behaviours associated with varying prevalence of HPV infection. 
We will survey 200 MSM aged 16-20 who just started their sexual life. We will use a questionnaire to collect information of socio-demographic characteristics, lifetime sexual experience, recent sexual experience, the most recent sexual contact, STIs/HIV history and testing history, HPV knowledge and attitude, smoking/alcohol/drug/circumcision. We will also collect oral, penile and anal samples as well as blood samples to test for HPV DNA, mRNA and antibody.

The study will include four visits in the 12-month period. In each visit, participants will be asked to fill a questionnaire and provide oral, penile and anal samples as well as blood samples. 

Each participant will receive $25 at each visit as compensation for their time. All participants will be offered free HPV vaccine at the end of the study.</summary>
    <trialwebsite>http://www.hyper.org.au/index.htm</trialwebsite>
    <publication>NIl to date</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Ethics committee</ethicname>
      <ethicaddress>The Alfred 

P.O Box 315
Prahran. Vic. 3181.</ethicaddress>
      <ethicapprovaldate>27/07/2010</ethicapprovaldate>
      <hrec>1/10/0174</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>christopher Fairley</name>
      <address>Alfred Health 
Melbourne Sexual Health Centre
580 Swanston Street Carlton Vic 3053</address>
      <phone>61 3 9341 6241</phone>
      <fax>61 3 9347 6757</fax>
      <email>cfairley@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Christopher Fairley</name>
      <address>Alfred Health 
Melbourne Sexual Health Centre
580 Swanston Street Carlton Vic 3053</address>
      <phone>61 3 9341 6241</phone>
      <fax>61 3 9347 6757</fax>
      <email>cfairley@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>christopher Fairley</name>
      <address>Alfred Health 
Melbourne Sexual Health Centre
580 Swanston Street Carlton Vic 3053</address>
      <phone>61 3 9341 6241</phone>
      <fax>61 3 9347 6757</fax>
      <email>cfairley@unimelb.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>